

Prof. ŞUAYİB YALÇIN

Personal Information

Office Phone: [+90 312 467 3030](tel:+903124673030)

Fax Phone: [+90 312 467 1313](tel:+903124671313)

Email: syalcin@hacettepe.edu.tr

Education Information

Expertise In Medicine, Hacettepe Üniversitesi, Tıp Fakültesi, Turkey 1983 - 1989

Research Areas

Medicine, Health Sciences, Internal Medicine Sciences, Internal Diseases , Oncology

Professional Experience

Surgeon General, Hacettepe Üniversitesi, Tıp Fakültesi, 2008 - 2012

Head of Department, Hacettepe Üniversitesi, Kanser Enstitüsü , Klinik Onkoloji Anabilim Dalı, 2009 - 2011

Deputy Chief Physician, Hacettepe Üniversitesi, Hacettepe Tıp Fakültesi, 2002 - 2008

Advising Theses

YALÇIN Ş., Mide kanseri tanısı konmuş yetişkin bireylerin yaşam tarzı ve beslenme alışkanlıklarının değerlendirilmesi, Post Graduate, E.YASSIBAŞ(Student), 2009

Articles Published in Journals That Entered SCI, SSCI and AHCI Indexes

- I. **A Challenging Task: Identifying Patients with Cancer of Unknown Primary (CUP) According to ESMO Guidelines: The CUPISCO Trial Experience**
Pauli C., Bochtler T., Mileskin L., Baciarello G., Losa F., Ross J. S. , Pentheroudakis G., Zarkavelis G., YALÇIN Ş., ÖZGÜROĞLU M., et al.
ONCOLOGIST, 2021 (Journal Indexed in SCI)
- II. **Poorer baseline performance status is associated with increased thromboembolism risk in metastatic cancer patients treated with immunotherapy**
GÜVEN D. C. , AKSUN M. S. , ŞAHİN T. K. , AKTEPE O. H. , YILDIRIM H. Ç. , TABAN H., Ceylan F., KERTMEN N., ARIK Z., DİZDAR Ö., et al.
SUPPORTIVE CARE IN CANCER, 2021 (Journal Indexed in SCI)
- III. **V600E and Non-V600E BRAF Mutations in Colorectal Cancer: Clinicopathologic Correlations in a Single Institution**
ŞİMŞEK C., LAÇIN Ş., Ece E., YALÇIN Ş.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.31, no.1, pp.43-49, 2021 (Journal Indexed in SCI)
- IV. **The Prognostic Value of Circulating VEGF-A Level in Patients With Hepatocellular Cancer**
Lacın S., YALÇIN Ş.

TECHNOLOGY IN CANCER RESEARCH & TREATMENT, vol.19, 2020 (Journal Indexed in SCI)

- V. **Impact of Integrating Insulin-Like Growth Factor 1 Levels into Model for End-Stage Liver Disease Score for Survival Prediction in Hepatocellular Carcinoma Patients**
Abdel-Wahab R., Hassan M. M. , George B., Pestana R. C. , Xiao L., Lacin S., YALÇIN Ş., Shalaby A. S. , Al-Shamsi H. O. , Raghav K., et al.
ONCOLOGY, vol.98, no.12, pp.836-846, 2020 (Journal Indexed in SCI)
- VI. **Clinicopathologic Features of Gastroenteropancreatic Neuroendocrine Tumors: A Single-center Experience**
AKIN TELLİ T., Esin E., YALÇIN Ş.
BALKAN MEDICAL JOURNAL, vol.37, no.5, pp.281-286, 2020 (Journal Indexed in SCI)
- VII. **Health-related quality of life associated with trifluridine/tipiracil in heavily pretreated metastatic gastric cancer: results from TAGS**
Tabernero J., Alsina M., Shitara K., Doi T., Dvorkin M., Mansoor W., Arkenau H., Prokharau A., Ghidini M., Faustino C., et al.
GASTRIC CANCER, vol.23, no.4, pp.689-698, 2020 (Journal Indexed in SCI)
- VIII. **Anti-prostate cancer activity of a nanoformulation of the spleen tyrosine kinase (SYK) inhibitor C61**
ŞAHİN T. K. , AKTEPE O. H. , Uckun F. M. , YALÇIN Ş.
ANTI-CANCER DRUGS, vol.31, no.6, pp.609-616, 2020 (Journal Indexed in SCI)
- IX. **Quality of life study of patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma treated with gemcitabine plus nab-paclitaxel versus gemcitabine alone: AX-PANC-SY001, a randomized phase-2 study**
YALÇIN Ş., DANE F., Oksuzoglu B., Ozdemir N. Y. , Isikdogan A., ÖZKAN M., Demirag G. G. , COŞKUN H. Ş. , KARABULUT B., Evrensel T., et al.
BMC CANCER, vol.20, no.1, 2020 (Journal Indexed in SCI)
- X. **Safety and efficacy of regorafenib in patients with treatment-refractory metastatic colorectal cancer in Turkey: the single-arm, open-label REGARD study**
Dane F., Ozgurdal K., YALÇIN Ş., BENEKLİ M., Aykan N. F. , YÜCEL İ., ÖZKAN M., EVRENSEL T., Sevinc A., COŞKUN H. Ş. , et al.
BMJ OPEN, vol.10, no.3, 2020 (Journal Indexed in SCI)
- XI. **Prognostic value of the 2017 World Health Organization Classification System for gastric neuroendocrine tumors: A single-center experience**
Karakas Y., Lacin S., KURTULAN O., Esin E., Sunar V., SÖKMENSÜER C., KILIÇKAP S., YALÇIN Ş.
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.31, no.2, pp.91-98, 2020 (Journal Indexed in SCI)
- XII. **Prognostic Significance of Serum Insulin-Like Growth Factor-1 in Hepatocellular Cancer Patients: A Validation Study**
Lacin S., YALÇIN Ş., Karakas Y., Hassan M. M. , Amin H., Mohamed Y. I. , Rashid A., Morris J. S. , Xiao L., Qayyum A., et al.
JOURNAL OF HEPATOCELLULAR CARCINOMA, vol.7, pp.143-153, 2020 (Journal Indexed in SCI)
- XIII. **The Effects of Different Treatment Modalities on the Disease Course and Survival in Patients with Hepatocellular Cancer**
Lacin S., Karakas Y., DİZDAR Ö., KILIÇKAP S., Hassan M. M. , Xiao L., Kaseb A. O. , YALÇIN Ş.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.30, no.2, pp.94-102, 2020 (Journal Indexed in SCI)
- XIV. **Nutritional Aspect of Cancer Care in Medical Oncology Patients**
YALÇIN Ş., GÜMÜŞ M., Oksuzoglu B., ÖZDEMİR F., EVRENSEL T., Sarioglu A. A. , ŞAHİN B., Mandel N. M. , GÖKER E.
CLINICAL THERAPEUTICS, vol.41, no.11, pp.2382-2396, 2019 (Journal Indexed in SCI)
- XV. **Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP)**
Riechelmann R. P. , Srimuninnimit V., Bordonaro R., Kavan P., Di Bartolomeo M., Maiello E., ÇİÇİN İ., Garcia-Alfonso P., Chau I., Fedyanin M. Y. , et al.
CLINICAL COLORECTAL CANCER, vol.18, no.3, pp.183-194, 2019 (Journal Indexed in SCI)
- XVI. **Concomitant RAS and BRAF mutation in colorectal cancer - A report of 7 cases**

- Ates O., YALÇIN Ş.
INDIAN JOURNAL OF CANCER, vol.56, no.2, pp.176-179, 2019 (Journal Indexed in SCI)
- XVII. **The frequency and predictors of persistent amenorrhea in premenopausal women with colorectal cancer who received adjuvant chemotherapy**
ŞAHİN T., DİZDAR Ö., Ozdemir N., Zengin N., Ates O., Oksuzoglu B., ŞENDUR M. A. N. , Bilgin B., DEMİR M., BOZBULUT U. B. , et al.
ANTI-CANCER DRUGS, vol.30, no.3, pp.289-294, 2019 (Journal Indexed in SCI)
- XVIII. **First-line treatment choices of Turkish medical oncologists in metastatic colorectal cancer: A survey study**
Beypinar I., ARAZ M., UYSAL M., YALÇIN Ş.
JOURNAL OF BUON, vol.24, no.1, pp.68-76, 2019 (Journal Indexed in SCI)
- XIX. **Impact of tivozanib on patient outcomes in treatment of advanced renal cell carcinoma**
YALÇIN Ş., Lacin S.
CANCER MANAGEMENT AND RESEARCH, vol.11, pp.7779-7785, 2019 (Journal Indexed in SCI)
- XX. **Metronomic Chemotherapy: A Systematic Review of the Literature and Clinical Experience**
ŞİMŞEK C., Esin E., YALÇIN Ş.
JOURNAL OF ONCOLOGY, vol.2019, 2019 (Journal Indexed in SCI)
- XXI. **Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial**
Shitara K., Doi T., Dvorkin M., Mansoor W., Arkenau H., Prokharau A., Alsina M., Ghidini M., Faustino C., Gorbunova V., et al.
LANCET ONCOLOGY, vol.19, no.11, pp.1437-1448, 2018 (Journal Indexed in SCI)
- XXII. **Real world survival data of a rare malignancy: Anal cancer results in HIV negative patients from Turkey**
ESİN E., YILDIZ F., Lacin S., KARAKAS Y., GÜLTEKİN M., DİZDAR Ö., YALÇIN Ş.
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.29, no.4, pp.411-418, 2018 (Journal Indexed in SCI)
- XXIII. **A correlation study of fluorouracil pharmacodynamics with clinical efficacy and toxicity**
Esin E., Telli T. A. , YÜCE D., YALÇIN Ş.
TUMORI J, vol.104, no.3, pp.157-164, 2018 (Journal Indexed in SCI)
- XXIV. **Clinicopathologic features of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): A single-center experience.**
Telli T. A. , Esin E., Yalcin S.
JOURNAL OF CLINICAL ONCOLOGY, vol.36, no.15, 2018 (Journal Indexed in SCI)
- XXV. **Recent advances in the management of pancreatic adenocarcinoma**
Karakas Y., LAÇİN Ş., YALÇIN Ş.
EXPERT REVIEW OF ANTICANCER THERAPY, vol.18, no.1, pp.51-62, 2018 (Journal Indexed in SCI)
- XXVI. **A national, multicenter, non-interventional, observational study on treatment patterns in patients with metastatic renal cell carcinoma in Turkey - NOTES study**
YALÇIN Ş., Yildiz R., Dane F., Karaoglu A., Oksuzoglu B., ÖZYILKAN Ö., Sevinc A., ÖZDEMİR F., TURNA Z. H. , Uslu R., et al.
ONCOTARGETS AND THERAPY, vol.11, pp.1223-1228, 2018 (Journal Indexed in SCI)
- XXVII. **Gastroenteropancreatic neuroendocrine tumors: recommendations of Turkish multidisciplinary neuroendocrine tumor study group on diagnosis, treatment and follow-up**
YALÇIN Ş., BAYRAM F., ERDAMAR ÇETİN A. S. , Kucuk O., ORUÇ N., Coker A.
ARCHIVES OF MEDICAL SCIENCE, vol.13, no.2, pp.271-282, 2017 (Journal Indexed in SCI)
- XXVIII. **Renal cell cancer: overview of the current therapeutic landscape**
ERMAN M., Benekli M., Basaran M., BAVBEK S., Buyukberber S., Coskun U., DEMİR G., KARABULUT B., OKSUZOGLU B., ÖZKAN M., et al.
EXPERT REVIEW OF ANTICANCER THERAPY, vol.16, no.9, pp.955-968, 2016 (Journal Indexed in SCI)
- XXIX. **Maternal risk factors associated with lead, mercury and cadmium levels in umbilical cord blood, breast milk and newborn hair**

- Dursun A., YURDAKÖK K., YALÇIN Ş., Tekinalp G., Aykut O., Orhan G., Morgil G. K.
JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE, vol.29, no.6, pp.954-961, 2016 (Journal Indexed in SCI)
- XXX. **A case of acanthosis nigricans as a paraneoplastic syndrome with squamous cell lung cancer**
Karakas Y., Esin E., LAÇİN Ş., Ceyhan K., HEPER A., YALÇIN Ş.
ONCOTARGETS AND THERAPY, vol.9, pp.4815-4820, 2016 (Journal Indexed in SCI)
- XXXI. **Evaluation of c-Met, HGF, and HER-2 expressions in gastric carcinoma and their association with other clinicopathological factors**
Yildiz Y., SÖKMENSÜER C., YALÇIN Ş.
ONCOTARGETS AND THERAPY, vol.9, pp.5809-5817, 2016 (Journal Indexed in SCI)
- XXXII. **Maintenance strategy in metastatic colorectal cancer: A systematic review**
Esin E., YALÇIN Ş.
CANCER TREATMENT REVIEWS, vol.42, pp.82-90, 2016 (Journal Indexed in SCI)
- XXXIII. **Effects of infrared treatment on tocopherols, total phenolics and antioxidant activity of soybean samples**
YALÇIN Ş., BAŞMAN A.
QUALITY ASSURANCE AND SAFETY OF CROPS & FOODS, vol.8, no.2, pp.273-281, 2016 (Journal Indexed in SCI)
- XXXIV. **Clinical Outcomes of Patients With Advanced Gastrointestinal Stromal Tumors: Safety and Efficacy in a Worldwide Treatment-Use Trial of Sunitinib**
Reichardt P., Kang Y., Rutkowski P., Schuette J., Rosen L. S. , Seddon B., YALÇIN Ş., Gelderblom H., Williams C. C. , Fumagalli E., et al.
CANCER, vol.121, no.9, pp.1405-1413, 2015 (Journal Indexed in SCI)
- XXXV. **Epidemiology of colorectal cancer in Turkey: A cross-sectional disease registry study (A Turkish Oncology Group trial)**
Aykan N. F. , YALÇIN Ş., Turhal N. S. , Ozdogan M., Demir G., ÖZKAN M., YAREN A., Camci C., AKBULUT H., Artac M., et al.
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.26, no.2, pp.145-153, 2015 (Journal Indexed in SCI)
- XXXVI. **Metastatic medullary thyroid cancer: a dramatic response to a systemic chemotherapy (temozolomide and capecitabine) regimen**
LAÇİN Ş., Esin E., Karakas Y., YALÇIN Ş.
ONCOTARGETS AND THERAPY, vol.8, pp.1039-1042, 2015 (Journal Indexed in SCI)
- XXXVII. **Efficacy of sorafenib in advanced differentiated and medullary thyroid cancer: experience in a Turkish population**
BENEKLİ M., YALÇIN Ş., ÖZKAN M., ELKIRAN E. T. , Sevinc A., ÇABUK D., COŞKUN H. Ş. , Oksuzoglu B., Bayar B., Akbulat A., et al.
ONCOTARGETS AND THERAPY, vol.8, pp.1-5, 2015 (Journal Indexed in SCI)
- XXXVIII. **Docetaxel, cisplatin, and fluorouracil combination in neoadjuvant setting in the treatment of locally advanced gastric adenocarcinoma: Phase II NEOTAX study**
Ozdemir N., Abali H., Vural M., YALÇIN Ş., Oksuzoglu B., Civelek B., Oguz D., Bostanci B., Yalcin B., Zengin N.
CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol.74, no.6, pp.1139-1147, 2014 (Journal Indexed in SCI)
- XXXIX. **EVALUATION OF QUALITY OF LIFE AND ANXIETY AND DEPRESISON LEVELS IN PATIENTS RECEIVING CHEMOTHERAPY FOR COLORECTAL CANCER: IMPACT OF PATIENT EDUCATION BEFORE TREATMENT INITIATION**
Yalcin S., Polat U., Arpacı A., Demir S., Erdal S.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, vol.10, pp.181, 2014 (Journal Indexed in SCI)
- XL. **Transient hypertrophic pyloric stenosis due to prostoglandin infusion**
Sayer T., YALÇIN Ş., Bozkaya D., YIĞİT Ş., TANYEL F. C.
JOURNAL OF PERINATOLOGY, vol.34, no.10, pp.800-801, 2014 (Journal Indexed in SCI)
- XLI. **End-of-study results of Turkish gastric cancer patients from the global REGATE study**
YALÇIN Ş., Gumus M., KILIÇKAP S., Alkis N., Ilhan M., Oksuzoglu B., Orhan B., Unsal M., TEKİN S. B. , Yalcin B., et al.
JOURNAL OF BUON, vol.19, no.2, pp.377-387, 2014 (Journal Indexed in SCI)
- XLII. **Ultrasound Scanning of the Proximal Plexus in Diabetic Cervical Radiculoplexopathy**

- Yalcin S, Kara M, Tiftik T, Erden E, Ersoz M, Ozcakar L.
WEST INDIAN MEDICAL JOURNAL, vol.63, no.2, pp.208-209, 2014 (Journal Indexed in SCI)
- XLIII. **Analysis of Resected Gastric Cancer in Turkish Population**
Demir G, Unsal D, Zengin N, ER Ö, Dane F, YALÇIN Ş.
HEPATO-GASTROENTEROLOGY, vol.61, no.129, pp.259-266, 2014 (Journal Indexed in SCI)
- XLIV. **Neuropathic cancer pain: What we are dealing with? How to manage it?**
Esin E, YALÇIN Ş.
ONCOTARGETS AND THERAPY, vol.7, pp.599-618, 2014 (Journal Indexed in SCI)
- XLV. **Personalized treatment is better than one treatment fits all in the management of patients with mCRC: a consensus statement**
YALÇIN Ş, Trad D, Kader Y. A. , Halawani H, Demir O. G. , Mall R, Meshcheryakov A, Nasr F, Nosworthy A, Osinsky D., et al.
FUTURE ONCOLOGY, vol.10, no.16, pp.2643-2657, 2014 (Journal Indexed in SCI)
- XLVI. **Low ERCC1 expression is associated with prolonged survival in patients with bladder cancer receiving platinum-based neoadjuvant chemotherapy**
OZCAN M. F. , Dizdar O, DINCER N, BALCI S, Guler G, GOK B, PEKTAS G, SEKER M. M. , AKSOY S, Arslan C, et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, vol.31, no.8, pp.1709-1715, 2013 (Journal Indexed in SCI)
- XLVII. **Increasing performance of a hospital-based cancer registry: Hacettepe University hospitals experience**
Kutluk T, HAYRAN K. M. , Kilickap S, Yuce D, Celik I, Erman M, Yalcin S.
JOURNAL OF BUON, vol.18, no.4, pp.1088-1096, 2013 (Journal Indexed in SCI)
- XLVIII. **Breast cancer in octogenarian women: clinical characteristics and outcome**
Kuzan T. Y. , Koca E, Dizdar O, Arslan C, Eren T, Yalcin S, Kucukoztas N, Aksoy S, Rahatli S, Dede D. S. , et al.
JOURNAL OF BUON, vol.18, no.2, pp.328-334, 2013 (Journal Indexed in SCI)
- XLIX. **Transarterial Chemo and Radioembolization (Yttrium90) of Hepatic Metastasis of Neuroendocrine Tumors: Single Center Experience**
Ozkan F, PEYNİRCİOĞLU B., ÇİL B. E. , Yurttutan N, YALÇIN Ş, BALKANCI F.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.23, no.1, pp.20-27, 2013 (Journal Indexed in SCI)
- L. **Bevacizumab plus Capecitabine as Maintenance Therapy after Initial Bevacizumab plus XELOX Treatment in Previously Untreated Patients with Metastatic Colorectal Cancer: Phase III 'Stop and Go' Study Results - A Turkish Oncology Group Trial**
YALÇIN Ş, Uslu R, Dane F, Yilmaz U, Zengin N, Buyukunal E, Buyukberber S, Camci C, ŞENCAN O, Kilickap S, et al.
ONCOLOGY, vol.85, no.6, pp.328-335, 2013 (Journal Indexed in SCI)
- LI. **A review of the use of somatostatin analogs in oncology**
Keskin O, YALÇIN Ş.
ONCOTARGETS AND THERAPY, vol.6, pp.471-483, 2013 (Journal Indexed in SCI)
- LII. **Salmonella gastroenteritis in children (clinical characteristics and antibiotic susceptibility): comparison of the years 1995-2001 and 2002-2008**
Ince O. T. , YALÇIN Ş, YURDAKÖK K, ÖZMERT E. N. , Aydin A, Baris Z, Gur D.
TURKISH JOURNAL OF PEDIATRICS, vol.54, no.5, pp.465-473, 2012 (Journal Indexed in SCI)
- LIII. **Clinicopathological Characteristics of Hepatocellular Carcinoma in Turkey**
Dogan E, YALÇIN Ş, Koca D, Olmez A.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol.13, no.6, pp.2985-2990, 2012 (Journal Indexed in SCI)
- LIV. **Screening Colonoscopy Participation in Turkish Colorectal Cancer Patients and their First Degree Relatives**
KILIÇKAP S, ARSLAN Ç, Rama D, YALÇIN Ş.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol.13, no.6, pp.2829-2832, 2012 (Journal Indexed in SCI)
- LV. **Impact of Adjuvant Chemoradiotherapy for Rectal Cancer on the Long-Term Quality of Life and Late Side Effects: A Multicentric Clinical Evaluation by the Turkish Oncology Group**
Kilic D, Yalman D, Aksu G, ATASOY B. M. , Igdem S, DİNÇBAŞ H. F. , YALÇIN Ş.

- ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol.13, no.11, pp.5741-5746, 2012 (Journal Indexed in SCI)
- LVI. **Lack of Any Relationship between ABO and Rh Blood Groups and Clinicopathological Features in Patients with Gastrointestinal Stromal Tumors: Turkish Oncology Group**
ÜRÜN Y., Utkan G., YALÇIN Ş., COŞKUN H. Ş. , Kocer M., Ozdemir N. Y. , Kaplan M. A. , Arslan U. Y. , ÖZDEMİR F., ÖZTUNA D., et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol.13, no.8, pp.4129-4131, 2012 (Journal Indexed in SCI)
- LVII. **Utility of "Over D1" or D1 Nodal Dissections in Predicting Outcome of Patients with Gastric Adenocarcinoma Treated with Postoperative Concurrent Chemoradiotherapy**
SELEK U., Zorlu F., ÖZYİĞİT G., HÜR MÜZ P., YALÇIN Ş., CENGİZ M.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.22, no.4, pp.233-238, 2012 (Journal Indexed in SCI)
- LVIII. **Evaluation of Dietary and Life-Style Habits of Patients with Gastric Cancer: A Case-Control Study in Turkey**
YASSIBAŞ E., Arslan P., YALÇIN Ş.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol.13, no.5, pp.2291-2297, 2012 (Journal Indexed in SCI)
- LIX. **Nilotinib in Advanced Gastrointestinal Stromal Tumors after Imatinib and Sunitinib Therapy**
Dizdar O., YALÇIN Ş.
HEPATO-GASTROENTEROLOGY, vol.58, no.112, pp.2012-2014, 2011 (Journal Indexed in SCI)
- LX. **Breast milk lead and cadmium levels from suburban areas of Ankara**
Orun E., YALÇIN Ş., Aykut O., Orhan G., Morgil G. K. , YURDAKÖK K., Uzun R.
SCIENCE OF THE TOTAL ENVIRONMENT, vol.409, no.13, pp.2467-2472, 2011 (Journal Indexed in SCI)
- LXI. **Bevacizumab plus capecitabine as maintenance treatment after initial treatment with bevacizumab plus XELOX in previously untreated metastatic colorectal cancer: Updated findings from a randomized, multicenter phase III trial**
Yalcin S., Uslu R., Dane F., Yilmaz U., Zengin N., Buyukunal E., Buyukberber S., Camci C., Sencan O., Kilickap S.
JOURNAL OF CLINICAL ONCOLOGY, vol.29, no.15, 2011 (Journal Indexed in SCI)
- LXII. **Evaluation of sorafenib in combination with local microtherapy guided by gadolinium-EOB-DTPA enhanced MRI in patients with inoperable hepatocellular carcinoma.**
Ricke J., Schuette K., Graziadei I. W. , Jakob A., Verslype C., Sangro B., Walecki J., Kluempfen H. J. , Peynircioglu B., Yalcin S., et al.
JOURNAL OF CLINICAL ONCOLOGY, vol.29, no.15, 2011 (Journal Indexed in SCI)
- LXIII. **Nilotinib is Effective in Imatinib and Sunitinib Resistant GIST: A Case Report**
DİZDAR Ö., YALÇIN Ş.
HEPATO-GASTROENTEROLOGY, vol.58, no.107, pp.859-860, 2011 (Journal Indexed in SCI)
- LXIV. **The association between sociodemographic parameters and the use of complementary interventions in patients with cancer in Turkey: A Turkish Oncology Group study.**
Turhal N. S. , Kilickap S., Yalcin S., Sezgin C., Yamac D., Akbulut H., Ozyilkan O., Ozdemir F., Cabuk D., Sevinc A.
JOURNAL OF CLINICAL ONCOLOGY, vol.29, no.15, 2011 (Journal Indexed in SCI)
- LXV. **Advances in the systemic treatment of pancreatic neuroendocrine tumors**
Yalcin S.
CANCER TREATMENT REVIEWS, vol.37, no.2, pp.127-132, 2011 (Journal Indexed in SCI)
- LXVI. **Gastric cancer after cadaveric liver transplantation in a patient with autoimmune hepatitis: A case report and review of the literature**
ARSLAN Ç., KILIÇKAP S., YALÇIN Ş.
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.22, no.1, pp.73-76, 2011 (Journal Indexed in SCI)
- LXVII. **Profile of the colorectal (CRC) cancer (Ca) patients (PTS) in Turkey: A cross-sectional disease registry study-A Turkish Oncology Group trial**
Aykan N., Demir G., Disci R., Yalcin S., Turhal N. S. , Ozdogan M., Ozkan M., Yaren A., Camel C., Akbulut H.
JOURNAL OF CLINICAL ONCOLOGY, vol.29, no.4, 2011 (Journal Indexed in SCI)
- LXVIII. **A randomized, multicenter phase III trial of bevacizumab plus capecitabine as maintenance treatment after initial treatment with bevacizumab plus XELOX in previously untreated metastatic colorectal cancer**

- Yalcin S, Uslu R, Dane F, Yilmaz U, Zengin N, Buyukunal E, Buyukberber S, Camci C, Sencan O, Kilickap S.
JOURNAL OF CLINICAL ONCOLOGY, vol.29, no.4, 2011 (Journal Indexed in SCI)
- LXXIX. **The First Line Systemic Chemotherapy in Metastatic Gastric Carcinoma: A Comparison of Docetaxel, Cisplatin and Fluorouracil (DCF) Versus Cisplatin and Fluorouracil (CF); Versus Epirubicin, Cisplatin and Fluorouracil (ECF) Regimens in Clinical Setting**
KILIÇKAP S., YALÇIN Ş., ATEŞ Ö., Tekuzman G.
HEPATO-GASTROENTEROLOGY, vol.58, no.105, pp.208-212, 2011 (Journal Indexed in SCI)
- LXX. **Hepatitis A seroprevalence among infants aged 12 months in Ankara**
Ince O. T. , YALÇIN Ş., YURDAKÖK K., ÖZMERT E. N.
TURKISH JOURNAL OF PEDIATRICS, vol.53, no.1, pp.114-116, 2011 (Journal Indexed in SCI)
- LXXI. **Zinc supplementation and TNF-alpha levels in vaccinated cardiac patients**
YALÇIN Ş., Engur-Karasimav D., ALEHAN D., YURDAKÖK K., Ozkutlu S., COŞKUN T.
JOURNAL OF TRACE ELEMENTS IN MEDICINE AND BIOLOGY, vol.25, no.2, pp.85-90, 2011 (Journal Indexed in SCI)
- LXXII. **Why are they having infant colic? A nested case-control study**
YALÇIN Ş., ORUN E., MUTLU B., MADENDAG Y., Sinici I., DURSUN A., ÖZKARA H. A. , USTUNYURT Z., KUTLUK S., Yurdakok K.
PAEDIATRIC AND PERINATAL EPIDEMIOLOGY, vol.24, no.6, pp.584-596, 2010 (Journal Indexed in SCI)
- LXXIII. **Sensitivity and specificity of bloody diarrhea in shigella gastroenteritis**
ÖZMERT E. N. , ORUN E., ŞENGELEN M., YALÇIN Ş., YURDAKÖK K., GÜR D.
TURKISH JOURNAL OF PEDIATRICS, vol.52, no.5, pp.488-490, 2010 (Journal Indexed in SCI)
- LXXIV. **Serological response to influenza vaccine after hematopoietic stem cell transplantation**
YALÇIN Ş., Kondolot M., Albayrak N., Altas A. B. , Karacan Y., Kuskonmaz B. B. , AKSU S., Cetin M., GÖKER H., YURDAKÖK K., et al.
ANNALS OF HEMATOLOGY, vol.89, no.9, pp.913-918, 2010 (Journal Indexed in SCI)
- LXXV. **Measles, mumps, and rubella antibody status and response to immunization in children after therapy for acute lymphoblastic leukemia**
Aytac Ş. S. , YALÇIN Ş., Cetin M., Yetgin S., GÜMRÜK F., Tuncer M., YURDAKÖK K., Gurgey A.
Pediatric Hematology and Oncology, vol.27, no.5, pp.333-343, 2010 (Journal Indexed in SCI Expanded)
- LXXVI. **Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial**
Ocvirk J., Brodowicz T., Wrba F., Ciuleanu T. E. , Kurteva G., Beslija S., Koza I., Zsuzsanna Papai Z. P. , Messinger D., Yilmaz U., et al.
WORLD JOURNAL OF GASTROENTEROLOGY, vol.16, no.25, pp.3133-3143, 2010 (Journal Indexed in SCI)
- LXXVII. **FEEDING PRACTICES OF 12-23 MONTHS AGED CHILDREN IN TURKEY**
Koksal E., YALÇIN Ş., Tezel B., Pekcan G., Sahin S., Ozbas S., YURDAKÖK K., Tunc B., Altinsu T., Kose M., et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, vol.50, 2010 (Journal Indexed in SCI)
- LXXVIII. **Registry of Gastric Cancer Treatment Evaluation (REGATE): Staging and diagnosis of 10,124 patients (pts)**
Wu C., Soloviev V., Semkina E., Ter-Ovanesov M., Babu K. G. , Vila A., Yalcin S., Roth A., Ecstein-Fraisse E. B. , Bang Y.
JOURNAL OF CLINICAL ONCOLOGY, vol.28, no.15, 2010 (Journal Indexed in SCI)
- LXXIX. **Registry of Gastric Cancer Treatment Evaluation (REGATE): Regional differences in surgical approaches**
Ter-Ovanesov M., Kulig J., Munasyrov F., Bang Y., Yalcin S., Roth A., Zalcborg J. R. , Ecstein-Fraisse E. B. , Wu C.
JOURNAL OF CLINICAL ONCOLOGY, vol.28, no.15, 2010 (Journal Indexed in SCI)
- LXXX. **The awareness and knowledge levels of colorectal cancer (CRC) patients and their first-degree relatives (FDR) for CRC screening**
Arslan C., Kilickap S., Rama D., Yalcin S.
JOURNAL OF CLINICAL ONCOLOGY, vol.28, no.15, 2010 (Journal Indexed in SCI)
- LXXXI. **Registry of Gastric Cancer Treatment Evaluation (REGATE): Variation in nonsurgical therapies**
Yalcin S., Serraiwa M., Arbeloa P., Kang W., Bang Y., Gumus M., Wu C., Roth A., Ecstein-Fraisse E. B. , Ter-Ovanesov M.
JOURNAL OF CLINICAL ONCOLOGY, vol.28, no.15, 2010 (Journal Indexed in SCI)
- LXXXII. **Registry of Gastric Cancer Treatment Evaluation (REGATE): Geographic analysis of baseline**

characteristics of 10,124 patients (pts)

Zalberg J. R. , Mohandas K. M. , Kang Y., Bang Y., Ter-Ovanesov M., Ben Ahmed S., Wu C., Roth A., Ecstein-Fraisse E. B. , Yalcin S.

JOURNAL OF CLINICAL ONCOLOGY, vol.28, no.15, 2010 (Journal Indexed in SCI)

- LXXXIII. **The Factors that have a Role in Variability for Temperature**
YALÇIN Ş., Aydemir O., Erkul E., KARABULUT E., Akca T.
JOURNAL OF TROPICAL PEDIATRICS, vol.56, no.1, pp.53-59, 2010 (Journal Indexed in SCI)
- LXXXIV. **Factors associated with breastfeeding initiation time in a Baby-Friendly Hospital**
Orun E., YALÇIN Ş., Madendag Y., Ustunyurt-Eras Z., Kutluk S., YURDAKÖK K.
TURKISH JOURNAL OF PEDIATRICS, vol.52, no.1, pp.10-16, 2010 (Journal Indexed in SCI)
- LXXXV. **Maternal and environmental determinants of breast-milk mercury concentrations**
YALÇIN Ş., YURDAKÖK K., Yalcin S. S. , Engur-Karasimav D., COŞKUN T.
TURKISH JOURNAL OF PEDIATRICS, vol.52, no.1, pp.1-9, 2010 (Journal Indexed in SCI)
- LXXXVI. **Feeding on one side or both sides in a breast-feeding session**
KONDOLOT M., YALÇIN Ş., YURDAKÖK K.
PEDIATRICS INTERNATIONAL, vol.51, no.6, pp.817-820, 2009 (Journal Indexed in SCI)
- LXXXVII. **Seasonal and gender differences in hemoglobin value in infants at 5-7 months of age**
YALÇIN Ş., Dut R., YURDAKÖK K., Ozmert E.
TURKISH JOURNAL OF PEDIATRICS, vol.51, no.6, pp.572-577, 2009 (Journal Indexed in SCI)
- LXXXVIII. **Effects of early feed restriction on live performance, carcass characteristics, meat and liver composition, some blood parameters, heterophil-lymphocyte ratio, antibody production and tonic immobility duration**
Onbasilar E. E. , Yalcin S., Torlak E., Ozdemir P.
TROPICAL ANIMAL HEALTH AND PRODUCTION, vol.41, no.7, pp.1513-1519, 2009 (Journal Indexed in SCI)
- LXXXIX. **Quality of life of palliative chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction treated with irinotecan combined with 5-fluorouracil and folinic acid: results of a randomised phase III trial**
Curran D., Pozzo C., Zaluski J., Dank M., Barone C., Valvere V., YALÇIN Ş., Peschel C., Wenczl M., GÖKER E., et al.
QUALITY OF LIFE RESEARCH, vol.18, no.7, pp.853-861, 2009 (Journal Indexed in SCI)
- XC. **Changes in serum leptin concentrations in rats according to malnutrition models and effects of carnitine supplementation on catch-up growth**
ONBAŞILAR İ., YALÇIN Ş.
REVUE DE MEDECINE VETERINAIRE, vol.160, no.7, pp.362-369, 2009 (Journal Indexed in SCI)
- XCI. **Comparison of acute bloody and watery diarrhea: a case control study**
Kuskonmaz B. B. , YURDAKÖK K., YALÇIN Ş., Ozmert E.
TURKISH JOURNAL OF PEDIATRICS, vol.51, no.2, pp.133-140, 2009 (Journal Indexed in SCI)
- XCII. **Nutrition and Gastric Cancer in Turkey**
YALÇIN Ş.
NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL, vol.61, no.6, pp.900-902, 2009 (Journal Indexed in SCI)
- XCIII. **NFKB1-94 Insertion/Deletion ATTG Polymorphism in Gastroenteropancreatic Neuroendocrine Tumors**
Burnik F. S. , YALÇIN Ş.
CHEMOTHERAPY, vol.55, no.5, pp.381-385, 2009 (Journal Indexed in SCI)
- XCIV. **Effects of the usage of dried brewing yeast in the diets on the performance, egg traits and blood parameters in quails**
Yalcin S., Erol H., Oezsoy B., Onbasilar I., Yalcin S.
ANIMAL, vol.2, no.12, pp.1780-1785, 2008 (Journal Indexed in SCI)
- XCv. **Clinical presentation and management of Gastroesophageal reflux disease in a referral center in Turkey**
YALÇIN Ş., ÇİFTÇİ A. Ö. , Senocak M. E. , TANYEL F. C.
EUROPEAN JOURNAL OF PEDIATRIC SURGERY, vol.18, no.3, pp.180-184, 2008 (Journal Indexed in SCI)

- XCVI. Prophylactic use of acetaminophen in children vaccinated with diphtheria-tetanus-pertussis**
YALÇIN Ş., Gumus A., YURDAKÖK K.
WORLD JOURNAL OF PEDIATRICS, vol.4, no.2, pp.127-129, 2008 (Journal Indexed in SCI)
- XCVII. Validity of using pallor to detect children with mild anemia**
YURDAKÖK K., Guner S. N. , YALÇIN Ş.
PEDIATRICS INTERNATIONAL, vol.50, no.2, pp.232-234, 2008 (Journal Indexed in SCI)
- XCVIII. Sparing of previously irradiated skin from eriotinib-induced acneiform rash**
YALÇIN Ş., Dizdar O., Yalcin B., Goekoez Ö.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, vol.58, no.1, pp.178-179, 2008 (Journal Indexed in SCI)
- XCIX. Seasonal and gender differences in the prevalence of infant anemia**
YALÇIN Ş., Dut R., YURDAKÖK K., Ozmert E.
PEDIATRICS, vol.121, 2008 (Journal Indexed in SCI)
- C. Current medical treatment of pancreatic neuroendocrine tumors**
Yalcin S., Oyan B., Bayraktar Y.
HEPATO-GASTROENTEROLOGY, vol.54, no.73, pp.278-284, 2007 (Journal Indexed in SCI)
- CI. Lightning: A risk factor for squamous cell carcinoma of the skin**
Purnak T., Kilickap S., Aksoy S., Yalcin S.
CLINICAL ONCOLOGY, vol.18, no.8, pp.636, 2006 (Journal Indexed in SCI)
- CII. Cutaneous metastases of signet cell carcinoma of the rectum without accompanying visceral involvement**
Kilickap S., Aksoy S., Dincer M., Saglam E. A. , Yalcin S.
SOUTHERN MEDICAL JOURNAL, vol.99, no.10, pp.1137-1139, 2006 (Journal Indexed in SCI)
- CIII. Orbital metastasis from adenocarcinoma of the colon**
Dizdar O., Aksoy S., Kilickap S., Yalcin S.
SOUTHERN MEDICAL JOURNAL, vol.98, no.8, pp.846-847, 2005 (Journal Indexed in SCI)
- CIV. Common etiology of capecitabine and fluorouracil-induced coronary vasospasm in a colon cancer patient**
Aksoy S., KARACA B., DİNÇER M., Yalcin S.
ANNALS OF PHARMACOTHERAPY, vol.39, no.3, pp.573-574, 2005 (Journal Indexed in SCI)
- CV. Induction chemotherapy with cisplatin and 5-fluorouracil followed by chemoradiotherapy or radiotherapy alone in the treatment of locoregionally advanced resectable cancers of the larynx and hypopharynx: Results of single-center study of 45 patients**
Altundag O., Gullu I., Altundag K., Yalcin S., Ozyar E., Cengiz M., Akyol F., Yucel T., Hosal S., Sozeri B.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, vol.27, no.1, pp.15-21, 2005 (Journal Indexed in SCI)
- CVI. Salvage ifosfamide-doxorubicin chemotherapy in patients with recurrent nasopharyngeal carcinoma pretreated with cisplatin-based chemotherapy**
Altundag K., Aksoy S., Gullu I., Altundag O., Ozyar E., Yalcin S., Cengiz M., Akyol F.
MEDICAL ONCOLOGY, vol.21, no.3, pp.211-215, 2004 (Journal Indexed in SCI)
- CVII. Prognostic factors and outcome in 306 patients with diffuse large B-cell lymphoma (DLBCL)**
OYAN ULUÇ B., Tekuzman G., BARIŞTA İ., Ozisik Y., kars A., Turker A., YALÇIN Ş., Guler N., Koc Y., KANSU E.
ANNALS OF ONCOLOGY, vol.15, pp.153, 2004 (Journal Indexed in SCI)
- CVIII. Diagnosis and management of cholangiocarcinomas: A comprehensive review**
Yalcin S.
HEPATO-GASTROENTEROLOGY, vol.51, no.55, pp.43-50, 2004 (Journal Indexed in SCI)
- CIX. Biweekly irinotecan plus bolus 5-fluorouracil and folinic acid in patients with advanced stage colorectal cancer**
Yalcin S., Oksuzoglu B., Tekuzman G., Engin H., Celik I., Turker A., Barista I., Gullu I., Guler N., Altundag K., et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, vol.33, no.11, pp.580-583, 2003 (Journal Indexed in SCI)
- CX. Weekly irinotecan in patients with metastatic colorectal cancer failing 5-fluorouracil-based**

chemotherapy: Efficacy and prognostic factors

Karaoglu A, Yalcin S, Tekuzman G, Kars A, Celik I, Guler N, Ozisik Y, Turker A, Barista I, Gullu I.
TUMORI, vol.89, no.2, pp.141-145, 2003 (Journal Indexed in SCI)

- CXI. **Reactivation of hepatitis B virus infection in pancreatic cancer: a case report**
Oksuzoglu B, Kilickap S, Yalcin S.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, vol.32, no.12, pp.543-545, 2002 (Journal Indexed in SCI)
- CXII. **Modified ESHAP as salvage chemotherapy for recurrent or refractory non-Hodgkin's lymphoma: Results of a single-center study of 32 patients**
Ozturk M., Barista I, Altundag M., Turker A, Yalcin S., Celik I, Gullu I, Guler N., Ozisik Y., Kars A., et al.
CHEMOTHERAPY, vol.48, no.5, pp.252-258, 2002 (Journal Indexed in SCI)
- CXIII. **Role of self-expandable metal stents (SEMS) in colorectal malignancy**
Yalcin S, Singh S, Gagneja H, Kalha I, Patel M, Lenzi R, Kaw M.
AMERICAN JOURNAL OF GASTROENTEROLOGY, vol.97, no.9, 2002 (Journal Indexed in SCI)
- CXIV. **Abdominal pain in a diabetic myeloma patient with cirrhosis**
GÖNEN C, Oksuzoglu B, Yalcin S.
POSTGRADUATE MEDICAL JOURNAL, vol.78, no.920, pp.375-376, 2002 (Journal Indexed in SCI)
- CXV. **Squamous cell carcinoma of the tongue in a patient with Fanconi's anemia: a case report and review of the literature**
Oksuzoglu B, Yalcin S.
ANNALS OF HEMATOLOGY, vol.81, no.5, pp.294-298, 2002 (Journal Indexed in SCI)
- CXVI. **Phase II study of docetaxel in patients with pancreatic cancer previously untreated with cytotoxic chemotherapy**
Lenzi R, Yalcin S, Evans D, Abbruzzese J.
CANCER INVESTIGATION, vol.20, no.4, pp.464-472, 2002 (Journal Indexed in SCI)
- CXVII. **The effects of tannic acid and liginosulfonate treatments of sunflower seed meal on the digestibility and rumen degradability characteristics of some nutrients in rams**
Yalcin S, Sehu A, Guclu B, Onbasilar I, Sarifakiogullari K.
TURKISH JOURNAL OF VETERINARY & ANIMAL SCIENCES, vol.26, no.4, pp.805-813, 2002 (Journal Indexed in SCI)
- CXVIII. **Leptomeningeal infiltration of malignant mesothelioma**
Oksuzoglu B, Yalcin S, Erman M, Dagdelen S.
MEDICAL ONCOLOGY, vol.19, no.3, pp.167-169, 2002 (Journal Indexed in SCI)
- CXIX. **Generalized lymphadenopathy - A rare presentation of disseminated prostate cancer**
Oyan B, Engin H, Yalcin S.
MEDICAL ONCOLOGY, vol.19, no.3, pp.177-179, 2002 (Journal Indexed in SCI)
- CXX. **Syndrome of inappropriate antidiuretic hormone secretion (SIADH) associated with prostatic carcinoma**
Yalcin S, Erman M, Tekuzman G, Ruacan S.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, vol.23, no.4, pp.384-385, 2000 (Journal Indexed in SCI)
- CXXI. **Primary low grade B-cell lymphoma of the dura in an immunocompetent patient**
Altundag M., Ozisik Y., Yalcin S., Akyol F., Uner A.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, vol.19, no.2, pp.249-251, 2000 (Journal Indexed in SCI)
- CXXII. **Management of patients with cancer of unknown primary site - The Hainsworth/Greco article reviewed**
Lenzi R, Yalcin S.
ONCOLOGY-NEW YORK, vol.14, no.4, pp.576-578, 2000 (Journal Indexed in SCI)
- CXXIII. **Organ preservation by induction chemotherapy plus radiotherapy in locally advanced larynx and hypopharynx cancers: Preliminary results.**
Gullu Y, Altundag M, Yalcin S, Altundag O, Tekuzman G, Ozyar E, Akyol F, Yucel T, Hosal S, Kaya S.
ANNALS OF ONCOLOGY, vol.11, pp.94, 2000 (Journal Indexed in SCI)

- CXXIV. **Treatment of advanced soft tissue sarcomas with ifosfamide and doxorubicin combination chemotherapy**
Barista I, Tekuzman G, Yalcin S, Gullu I, Guler N, Ozisik Y, Kars A, Celik I, Turker A, Altundag K, et al.
JOURNAL OF SURGICAL ONCOLOGY, vol.73, no.1, pp.12-16, 2000 (Journal Indexed in SCI)
- CXXV. **DEVELOPMENT AND APPLICATION OF A SIMPLE EXPERT SYSTEM FOR THE INTERPRETATION OF THE ANTEPARTUM FETAL HEART-RATE TRACINGS (VERSION 88/2.29)**
BEKSAC M, OZDEMIR K, KARAKAS U, YALCIN S, KARAAGAOGLU E.
EUROPEAN JOURNAL OF OBSTETRICS GYNECOLOGY AND REPRODUCTIVE BIOLOGY, vol.37, no.2, pp.133-141, 1990 (Journal Indexed in SCI)
- CXXVI. **COMPUTERIZED ANALYSIS OF ANTEPARTUM FETAL HEART-RATE TRACINGS IN NORMAL PREGNANCIES (VERSION 88/2.29)**
BEKSAC M, KARAKAS U, YALCIN S, OZDEMIR K, SANLITURK E.
EUROPEAN JOURNAL OF OBSTETRICS GYNECOLOGY AND REPRODUCTIVE BIOLOGY, vol.37, no.2, pp.121-132, 1990 (Journal Indexed in SCI)

Articles Published in Other Journals

- I. **Stereotactic ablative radiotherapy for bone metastasis of gastrointestinal stromal tumor: Case report and review of the literature**
YILMAZ M. T. , GÜLTEKİN M., YALÇIN Ş., TUNCEL M., Gedikoglu G., YILDIZ F., CENGİZ M.
REPORTS OF PRACTICAL ONCOLOGY AND RADIOTHERAPY, vol.25, no.3, pp.331-335, 2020 (Journal Indexed in ESCI)
- II. **Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial**
YALÇIN Ş., ÖZGÜROĞLU M., shitara K., bang y. j. , bartolomeo m. d. , mandala m., ryu m.
Lancet, vol.392, no.10142, pp.123-133, 2018 (Refereed Journals of Other Institutions)
- III. **Prevalence of Complementary Medicine Use in Patients With Cancer: A Turkish Comprehensive Cancer Center Experience**
YALÇIN Ş., HÜRMÜZ P., McQuinn L., Naing A.
JOURNAL OF GLOBAL ONCOLOGY, vol.4, 2017 (Journal Indexed in ESCI)
- IV. **Bone Metastasis from Gastric Cancer: The Incidence, Clinicopathological Features, and Influence on Survival**
Turkoz F. P. , Solak M., KILIÇKAP S., Ulas A., Esbah O., Oksuzoglu B., YALÇIN Ş.
JOURNAL OF GASTRIC CANCER, vol.14, no.3, pp.164-172, 2014 (Journal Indexed in ESCI)
- V. **Evaluation of quality of life and anxiety and depression levels in patients receiving chemotherapy for colorectal cancer: impact of patient education before treatment initiation**
POLAT Ü., Arpacı A., DEMİR S., Erdal S., YALÇIN Ş.
JOURNAL OF GASTROINTESTINAL ONCOLOGY, vol.5, no.4, pp.270-275, 2014 (Journal Indexed in ESCI)
- VI. **Current and future systemic treatment options in metastatic pancreatic cancer**
Arslan C., YALÇIN Ş.
JOURNAL OF GASTROINTESTINAL ONCOLOGY, vol.5, no.4, pp.280-295, 2014 (Journal Indexed in ESCI)

Books & Book Chapters

- I. **Nutrition and Cachexia in Gastrointestinal Cancer Patients**
HALİL M. G. , Kuyumcu M. E. , DİZDAR Ö., ÜLGER Z., YALÇIN Ş.
in: Textbook of Gastrointestinal Oncology, Yalçın Şuayib, Philip A. Philip, Editor, Springer, pp.379-394, 2019
- II. **treatment of rectal cancer**
ARTAÇ M., elrayes b. f. , YALÇIN Ş., philip p. a.

- in: textbook of gastrointestinal cancer patients, Suayib Yalcin, Philip a. Philip, Editor, springer, pp.161-174, 2019
- III. **Hypoglycemia and Hyperglycemia in Critically Ill Cancer Patients**
OĞUZ S. H. , ÜNLÜTÜRK U., LAÇIN Ş., GÜRLEK Ö. A. , YALÇIN Ş.
in: Oncologic Critical Care, Nates J., Price K, Editor, springer, pp.1079-1091, 2019
- IV. **esophageal and gastroesophageal junction tumors**
YALÇIN Ş., DİZDAR Ö., KILIÇKAP S., cilbir e., philip p. a.
in: textbook of gastrointestinal oncology, Suayib Yalcin, Philip a. Philip, Editor, springer, pp.55-72, 2019
- V. **Mide kanseri insidansı ve epidemiyolojisi**
YALÇIN Ş., AYKAN N. F. , ÇİÇİN İ., MANDEL N. K.
in: İLERİ EVRE MİDE KANSERİNDE TEDAVİ YAKLAŞIMLARI, Yalçın Şuayib, Öksüzoğlu Berna, Editor, ORTADOĞU REKLAM TANITIM YAYINCILIK AŞ, pp.1-11, 2018
- VI. **Mide kanserinde tanı ve patoloji**
YALÇIN Ş., ÇİÇİN İ., AYKAN N. F. , MANDEL N. K.
in: İleri evre mide kanserinde tedavi yaklaşımları, Yalçın Şuayib, Öksüzoğlu Berna, Editor, Ortadoğu reklam tanıtım yayıncılık A.Ş, pp.12-18, 2018
- VII. **Evreleme ve Preoperatif değerlendirme**
YALÇIN Ş., ÇİÇİN İ., AYKAN N. F. , MANDEL N. K.
in: İleri evre mide kanserinde tedavi yaklaşımları, Yalçın Şuayib, Öksüzoğlu Berna, Editor, Ortadoğu reklam tanıtım yayıncılık A.Ş, pp.19-24, 2018

Refereed Congress / Symposium Publications in Proceedings

- I. **Definitive Chemoradiotherapy in Esophageal Squamous Cell Cancer: A Single Center Experience**
YILMAZ M. T. , HÜRMÜZ P., CENGİZ M., YÜCE D., ZORLU A. F. , AKYOL H. F. , YALÇIN Ş., ÖZYİĞİT G.
9th International Gastrointestinal Cancer Conference, İstanbul, Turkey, 6 - 08 December 2019
- II. **the role of neoadjuvant radiotherapy in rectal cancer: hacettepe university experience**
HÜRMÜZ P., TİLKİ B., YILDIZ F., ÖZYİĞİT G., EROL T., KONAN A., ZORLU A. F. , YALÇIN Ş., AKYOL H. F.
9th international gastrointestinal cancer conference, 6 - 08 December 2019
- III. **prognostic significance of igf-1 in hepatocellular cancer patients turkish validation study**
LAÇIN Ş., Karakas Y., Abdel Wahab R., HASSAN M., Lianchun X., KASEB A., YALÇIN Ş.
9 th international gastrointestinal cancer conference, 6 - 08 December 2019
- IV. **outcomes of patients with resected pancreatic ductal adenocarcinoma**
ceylan f., GÜVEN D. C. , çakır y., Hamaloglu E., Karakoc D., TÜRKER F. A. , KILIÇKAP S., YALÇIN Ş., DİZDAR Ö.
9th international gastrointestinal cancer conference, 6 - 08 December 2019
- V. **non-operative management of rectal cancer: hacettepe university experience**
TİLKİ B., HÜRMÜZ P., CENGİZ M., ZORLU A. F. , ÖZYİĞİT G., YILDIZ F., YALÇIN Ş., AKYOL H. F.
9th international gastrointestinal cancer conference, 6 - 08 December 2019
- VI. **DEFİNİTİVE CHEMORADİOTHERAPY İN ESOPHAGEAL S@UAMOUS CELL CANCER A SİNGLE CENTER EXPERİENCE**
HÜRMÜZ P., CENGİZ M., YÜCE D., ZORLU A. F. , AKYOL H. F. , YALÇIN Ş., ÖZYİĞİT G.
9 th international gastrointestinal cancer conference, 6 - 08 December 2019
- VII. **importance of serum vegfa level in hepatocellular cancer patients, its relationship with clinicopathologic parameters**
LAÇIN Ş., Karakas Y., YALÇIN Ş.
9 th international gastrointestinal cancer conference, 6 - 08 December 2019
- VIII. **A Single Center Experience of Neoadjuvant Radiotherapy in Rectal Cancer**
HÜRMÜZ P., TİLKİ B., CENGİZ M., YILDIZ F., ÖZYİĞİT G., EROL T., KONAN A., ZORLU A. F. , YALÇIN Ş., AKYOL H. F.
6th CONGRESS OF THEMEDITERRANEAN MULTIDISCIPLINARY ONCOLOGY FORUM3rd INTERNATIONAL CONGRESS ON ONCOLOGICAL SCIENCES, 27 November - 01 December 2019, vol.5
- IX. **The Role of Radiotherapy /- Chemotherapy in the treatment of Rectal Cancer: Single Center**

Experience

TILKİ B., HÜR MÜZ P., CENGİZ M., YILDIZ F., ZORLU A. F., ÖZYİĞİT G., YALÇIN Ş., AKYOL H. F.

6th CONGRESS OF THEMEDITERRANEAN MULTIDISCIPLINARY ONCOLOGY FORUM3rd INTERNATIONAL CONGRESS ON ONCOLOGICAL SCIENCES, 27 November - 01 December 2019, vol.5

- X. **Clinical features and prognosis of patients with liposarcoma: Single-center experience.**
Demir M., Guven D. C. , Aktas B. Y. , Guner G., Aktepe O. H. , Taban H., Kilickap S., Kars A., Turker A, Yalcin S., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2019, vol.37
- XI. **Analysis of symptoms and functional HRQoL scales in TAGS, a phase III trial of trifluridine/tipiracil (FTD/TPI) in metastatic gastric cancer (mGC).**
Alsina M., Taberbero J., Shitara K., Doi T., Dvorkin M., Mansoor W., Arkenau H., Prokharau A., Ghidini M., Faustino C., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2019, vol.37
- XII. **COMBINATION OF OxALIPLATIN, CAPECITABINE, t r a s t u z u m a b a n d c h e m o r a d i o t h e r a p y INPATIENTS WITH GASTRIC CANCER**
ABALI H., YALÇIN Ş., ÖNAL H. C. , DANE F., ÇAKMAK ÖKSÜZOĞLU Ö. B. , ÖZDEMİR N., MERTSOYLU H., ARTAÇ M., camcı c., başol f., et al.
8 th INTERNATIONALGASTROINTESTINALCANCER CONFERENCE, 7 - 09 December 2018
- XIII. **Kolorektal Kanserde 16S rDNA Sekanslama ile Oral Mikrobiyom Analizi**
GÜVEN D. C. , ERGÜNAY K., BRINKMANN A., ALP A., AKDOĞAN KITTANA F. N. , AKYÖN YILMAZ Y., YILMAZ E., KARAKOÇ D., HAMALOĞLU E., YALÇIN Ş., et al.
2. Ulusal immünoterapi ve Onkoloji Kongresi, Antalya, Turkey, 31 October - 04 November 2018
- XIV. **A study of the combination of oxaliplatin, capecitabine, and trastuzumab and chemo-radiotherapy in the adjuvant setting in operated patients with HER2+gastric or gastroesophageal junction cancer (TOXAG study).**
Abali H., Yalcin S., Onal C., Dane F., Oksuzoglu B., Ozdemir N., Mertsoylu H., Artac M., Camci C., Karabulut B., et al.
Gastrointestinal Cancers Symposium, San-Francisco, Costa Rica, 18 - 20 January 2018, vol.36
- XV. **Economic Burden of Gastric Cancer in Turkey**
BİLİCİ A., GÜMÜŞ M., MALHAN B. S. , Öksüz E., ÇAKMAK ÖKSÜZOĞLU Ö. B. , YALÇIN Ş.
ISPOR 20th Annual European Congress, 4 - 08 November 2017
- XVI. **Modified IPCW model: A method for adjusting for bias in the estimation of overall survival due to the use of second and third line therapies in locally advanced or metastatic pancreatic cancer patients.**
Escobar N. E. I. , Luaces P. L. , Valdes L. S. , Silva C. V. , Ramos T. C. , Strumberg D., Schultheis B., Ebert M. P. , Kerkhoff A., Hofheinz R., et al.
53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, Illinois, United States Of America, 2 - 07 June 2017, vol.35
- XVII. **Beyin Tumorlerinde Serum Peptidomik Analiz**
PINAR A., KUTLUK M. T. , Mut A. M. , KARAHAN S., AKALAN N., YALÇIN Ş., HASÇELİK A. G.
22. Ulusal Kanser Kongresi, Turkey, 19 - 23 April 2017
- XVIII. **FREQUENCY OF CHEMOTHERAPY INDUCED AMENORRHEA IN WOMEN WITH COLORECTALCANCER**
ŞAHİN T., DİZDAR Ö., ÖZDEMİR N., ZENGİN N., ATEŞ Ö., ÇAKMAK ÖKSÜZOĞLU Ö. B. , ŞENDUR M. A. N. , BİLGİN B., Bozkurt U. B. , demir m., et al.
International Congress on Oncological Sciences, 27 September - 01 October 2017
- XIX. **A study of the combination of oxaliplatin, capecitabine, and herceptin (trastuzumab) and chemoradiotherapy in the adjuvant setting in operated patients with HER2+gastric or gastro-esophageal junction cancer (TOXAG study).**
Abali H., Yalcin S., Onal H. C. , Dane F., Oksuzoglu B., Ozdemir N., Mertsoylu H., Artac M., Camci C., Karabulut B., et al.
Gastrointestinal Cancers Symposium, San-Francisco, Costa Rica, 21 - 23 January 2016, vol.34
- XX. **Signet ring cell carcinoma of breast: Single center experience.**

AKIN S., DIKER O., KERTMEN N., ATEŞ Ö., DİZDAR Ö., YALÇIN Ş., Altundag K.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33

- XXI. **Extramedullary relapses after allogeneic stem cell transplantation for leukemia: Clinical characteristics, cumulative incidence and risk factors**
Goker H., Gunes G., Demiroglu H., Malkan U. Y. , Haznedaroglu I., Sayinalp N., Etgul S., Eliacik E., Aslan T., Isik A., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33
- XXII. **frequency of c Met HGF and HER 2 expression and evaluation of their association with clinicopathological and prognostic factors in gastric cancer**
YALÇIN Ş., yetkin y., SÖKMENSÜER C.
gastrointestinal cancers symposium 2015, 15 - 17 January 2015
- XXIII. **Frequency of c-Met, HGF, and HER-2 expression and evaluation of their association with clinicopathologic and prognostic factors in gastric cancer.**
YALÇIN Ş., Yildiz Y., SÖKMENSÜER C.
Gastrointestinal Cancers Symposium, San-Francisco, Costa Rica, 15 - 17 January 2015, vol.33
- XXIV. **Sorafenib in combination with local microtherapy guided by gadolinium-EOB-DTPA enhanced MRI in patients with inoperable hepatocellular carcinoma (SORAMIC).**
Ricke J., Schutte K., Rosmorduc O., Peck-Radosavljevic M., Verslype C., Sangro B., Waleckl J., Klumpen H., Peynircioglu B., Yalcin S., et al.
50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, United States Of America, 30 May - 03 June 2014, vol.32
- XXV. **Predictors of outcome in patients with advanced nonseminomatous germ cell testicular tumors.**
Yetisyigit T., Babacan N., Urun Y., Seber S., Arpacı E., Cihan S., Ylirim N., Oksuzoglu O. B. , Aksoy S., Budakoglu B., et al.
50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, United States Of America, 30 May - 03 June 2014, vol.32
- XXVI. **Evaluation of the frequency of c-Met and HER2 expressions in gastric carcinoma and their association with clinicopathologic factors**
YALÇIN Ş., Yildiz Y., SÖKMENSÜER C.
Gastrointestinal Cancers Symposium, San-Francisco, Costa Rica, 16 - 18 January 2014, vol.32
- XXVII. **The impact of adjuvant delayed radiotherapy (RT) on survival in patients with resected periampullary adenocarcinomas.**
Yalcin S., Kertmen N., Yuce D., Yildiz F., Hamaloglu E.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31
- XXVIII. **Randomized phase II study of first-line everolimus plus bevacizumab (E plus B) versus interferon alpha-2a plus bevacizumab (I plus B) in patients (pts) with metastatic renal cell carcinoma (mRCC): Record-2 final overall survival (OS) and safety results**
Ravaud A., Barrios C. H. , Alekseev B. Y. , Tay M. H. , Agarwala S. S. , Yalcin S., Lin C., Shkolnik M., Matveev V., Anak O., et al.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31
- XXIX. **Phase II, randomized, double-blind placebo-controlled trial of nimotuzumab plus gemcitabine compared with gemcitabine alone in patients (pts) with advanced pancreatic cancer (PC)**
Strumberg D., Schultheis B., Ebert M. P. , Kerkhoff A., Hofheinz R. D. , Behringer D. M. , Schmidt W. E. , Goker E., De Dosso S., Kneba M., et al.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31

- XXX. **Bevacizumab (BEV) plus capecitabine as maintenance therapy after initial treatment with BEV plus XELOX in previously untreated patients (pts) with metastatic colorectal cancer (mCRC): Mature data from STOP and GO, a phase III, randomized, multicenter study**
Yalcin S, Uslu R, Dane F, Yilmaz U, Zengin N, Buyukunal E, Buyukberber S, Camci C, Sencan O, Kilickap S, et al.
48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 1 - 06 June 2012, vol.30
- XXXI. **Phase II study of adjuvant imatinib mesylate (IM) in patients after resection of primary gastrointestinal stromal tumor (GIST): Efficacy and safety at one year.**
Yalcin S, Buyukberber S, Yilmaz U, Lee P, Srimuninnimit V, Lin P, Elserafy M. M. , Manieh M, Sunpaweravong P, Istomin Y, et al.
48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 1 - 06 June 2012, vol.30
- XXXII. **Post-Progression Therapies in Patients with Advanced Neuroendocrine Tumors (NET): Analysis From the RADIANT-2 Trial**
Hobday T, Becerra C, YALÇIN Ş, Panneerselvam A, Saletan S, Hainsworth J.
76th Annual Scientific Meeting of the American-College-of-Gastroenterology, Washington, Kiribati, 28 October - 02 November 2011, vol.106
- XXXIII. **POST-STUDY TREATMENT OPTIONS ARE LIMITED IN PATIENTS WITH ADVANCED NET: ANALYSIS OF POST-PROGRESSION THERAPIES FROM THE RADIANT-2 TRIAL**
Peeters M, Becerra C, Panneerselvam A, Saletan S, YALÇIN Ş.
European-Society-for-Medical-Oncology (ESMO) 13th World Congress on Gastrointestinal Cancer, Barcelona, Spain, 22 - 25 June 2011, vol.22
- XXXIV. **Serological response to influenza vaccine haematopoietic stem cell transplantation patients**
YALÇIN Ş, Kondolot M, Albayrak N, Altas B, Karacan Y, KUŞKONMAZ B. B. , AKSU S, ÇETİN M, GÖKER H, YURDAKÖK K, et al.
36th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantat/9th Meeting of the EBMT Data-Management-Group/26th Meeting of the EBMT Nurses Group/2nd EBMT Qual Management Meeting, Vienna, Austria, 21 - 24 March 2010, vol.45
- XXXV. **Clinical profile of gastric cancer in Turkey: Factors effecting disease free survival and relapse (Turkish Oncology Group Study)**
Demir G, Zengin N, Yildiz O, Ozdamar S, Aykan F, Er O, Ilhan M, Turhal S, Yilmaz U, Yalcin S.
31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Turkey, 29 September - 03 October 2006, vol.17, pp.324-325
- XXXVI. **REGATE: What happens to gastric cancer treatment in the real world?**
Ter-Ovanesov M, Bang Y, Wu C, Yalcin S, Roth A, Zalberg J, Soloviev V, Oliveros R, Yankin A, Narvaez C.
Satellite Symposium on New Horizons for Gastric Cancer held in conjunction with the 8th World Congress on Gastrointestinal Cancer, Barcelona, Spain, 29 June 2006, vol.17, pp.31
- XXXVII. **Bone marrow metastasis in solid tumors: Clinical evaluation of 64 cases.**
Kilickap S, Erman M, Dincer M, Aksoy S, Harputluoglu H, Yalcin S.
41st Annual Meeting of the American-Society-of-Clinical-Oncology, Florida, United States Of America, 13 - 17 May 2005, vol.23
- XXXVIII. **Ifosfamide-doxorubicin combination in patients with locally recurrent or metastatic nasopharyngeal carcinoma pretreated with cisplatin based chemotherapy: Retrospective analysis of 21 patients.**
Altundag K, Aksoy S, Gullu I, Altundag O, Ozyar E, Yalcin S, Cengiz M, Akyol F.
40th Annual Meeting of the American-Society-of-Clinical-Oncology, Louisiana, United States Of America, 5 - 08 June 2004, vol.22
- XXXIX. **Clinicopathological features and outcome of primary gastric lymphoma: A series of 73 cases**
Oyan B, Tekuzman G, Barista I, Kars A, Turker A, Ozisik Y, Guler N, Baltali E, Yalcin S, Gullu I.
40th Annual Meeting of the American-Society-of-Clinical-Oncology, Louisiana, United States Of America, 5 - 08 June 2004, vol.22

Supported Projects

YALÇIN Ş., Project Supported by Higher Education Institutions, Kanser Hastalarında Tamamlayıcı Tıp Kullanımı Hacettepe Üniversitesi Deneyimi (Prevalence of Complementary Medicine Use in Cancer Patients Hacettepe University Experience), 2017 - 2020

Citations

Total Citations (WOS):1214

h-index (WOS):19